CervoMed Analyst Price Targets - Benzinga

CervoMed Inc

CRVONASDAQ

Trade with Public

Trade with Public

$2.24

-0.01-0.44%

最終更新: Oct 16, 7:07 PM

$2.30

0.04562.03%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較株式レポート

© 2026 Benzinga | All Rights Reserved

CervoMed Analyst Price Targets

Wall Street analyst price targets and consensus rating for CervoMed (CRVO).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

10Buy

Consensus RatingBuy# Analysts10Avg. Consensus PT$27Upside to Avg. PT+1057.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Aug 12, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Aug 10, 2026	Canaccord Genuity	Sumant Kulkarni	PT Cut	Buy	$27→$18
Jul 15, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Jul 13, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Jul 9, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Apr 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Apr 22, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Apr 8, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Mar 19, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Mar 18, 2026	Roth Capital	Boobalan Pachaiyappan	PT Cut	Buy	$19→$11
Mar 18, 2026	Chardan Capital	Daniil Gataulin	PT Raise	Buy	$15→$21
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Mar 5, 2026	Chardan Capital	Daniil Gataulin	Maintained	Buy	$15
Mar 4, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Feb 18, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Dec 18, 2025	Cantor Fitzgerald	Pete Stavropoulos	Initiate	Overweight	—
Dec 18, 2025	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$25
Dec 5, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31
Dec 2, 2025	D. Boral Capital	Jason Kolbert	Maintained	Buy	$31

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $18

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $27 to $18.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.

Benzinga Newsdesk